Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Pre-clinical Efficacy and Safety Pharmacology of PEGylated Recombinant Human Endostatin

Author(s): Lifang Guo*, Linbin Hua, Bin Hu* and Jing Wang*

Volume 24, Issue 3, 2024

Published on: 05 May, 2023

Page: [389 - 396] Pages: 8

DOI: 10.2174/1566524023666230331091757

Price: $65

Abstract

Introduction: This study aimed to outline the pre-clinical efficacy and safety pharmacology of PEGylated recombinant human endostatin (M2ES) according to the requirements of new drug application.

Methods: The purity of M2ES was evaluated by using silver staining. Transwell migration assay was applied to detect the bioactivity of M2ES in vitro. The antitumor efficacy of M2ES was evaluated in an athymic nude mouse xenograft model of pancreatic cancer (Panc-1) and gastric cancer (MNK45). BALB/C mice were treated with different doses of M2ES (6, 12 and 24 mg/kg) intravenously, both autonomic activity and cooperative sleep were monitored before and after drug administration.

Results: The apparent molecular weight of M2ES was about 50 kDa, and the purity was greater than 98%. Compared with the control group, M2ES significantly inhibits human micro-vascular endothelial cells (HMECs) migration in vitro. Notably, weekly administration of M2ES showed a significant antitumor efficacy when compared with the control group. Treatment of M2ES (24mg/kg or below) showed no obvious effect on both autonomic activity and hypnosis.

Conclusion: On the basis of the pre-clinical efficacy and safety pharmacology data of M2ES, M2ES can be authorized to carry out further clinical studies.

« Previous
[1]
O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-85.
[http://dx.doi.org/10.1016/S0092-8674(00)81848-6] [PMID: 9008168]
[2]
Poluzzi C, Iozzo RV, Schaefer L, et al. Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers. Adv Drug Deliv Rev 2016; 97: 156-73.
[http://dx.doi.org/10.1016/j.addr.2015.10.012] [PMID: 26518982]
[3]
Szarvas T, László V, vom Dorp F, et al. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients’ prognosis in bladder cancer. Int J Cancer 2012; 130(12): 2922-9.
[http://dx.doi.org/10.1002/ijc.26343] [PMID: 21815140]
[4]
Ständker L, Schrader M, Kanse SM, et al. Isolation and characterization of the circulating form of human endostatin. FEBS Lett 1997; 420(2-3): 129-33.
[http://dx.doi.org/10.1016/S0014-5793(97)01503-2] [PMID: 9459295]
[5]
Walia A, Yang JF, Huang Y, et al. Endostatin’s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta, Gen Subj 2015; 1850(12): 2422-38.
[http://dx.doi.org/10.1016/j.bbagen.2015.09.007] [PMID: 26367079]
[6]
Yoon SS, Eto H, Lin CM, et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999; 59(24): 6251-6.
[PMID: 10626820]
[7]
Sim BKL, MacDonald NJ, Gubish ER. Angiostatin and endostatin: Endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000; 19(1/2): 181-90.
[http://dx.doi.org/10.1023/A:1026551202548] [PMID: 11191058]
[8]
Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007; 110(8): 2899-906.
[http://dx.doi.org/10.1182/blood-2007-01-064428] [PMID: 17615292]
[9]
Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277(31): 27872-9.
[http://dx.doi.org/10.1074/jbc.M202771200] [PMID: 12029087]
[10]
Guo L, Song N, He T, et al. Endostatin inhibits the tumorigenesis of hemangioendothelioma via downregulation of CXCL1. Mol Carcinog 2015; 54(11): 1340-53.
[http://dx.doi.org/10.1002/mc.22210] [PMID: 25175281]
[11]
Mohajeri A, Sanaei S, Kiafar F, et al. The challenges of recombinant endostatin in clinical application: Focus on the different expression systems and molecular bioengineering. Adv Pharm Bull 2017; 7(1): 21-34.
[http://dx.doi.org/10.15171/apb.2017.004] [PMID: 28507934]
[12]
Honglian M, Zhouguang H, Fang PENG, et al. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials. Thorac Cancer 2020; 11(4): 898-906.
[http://dx.doi.org/10.1111/1759-7714.13333] [PMID: 32068962]
[13]
Wang ZQ, Wang DS, Wang FH, et al. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: A prospective, single-arm, open-label, phase II study. Invest New Drugs 2021; 39(2): 516-23.
[http://dx.doi.org/10.1007/s10637-020-01021-1] [PMID: 33070249]
[14]
Moschos SJ, Odoux C, Land SR, et al. Endostatin plus interferon-α2b therapy for metastatic melanoma: A novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 2007; 17(3): 193-200.
[http://dx.doi.org/10.1097/CMR.0b013e3281ad91a3] [PMID: 17505265]
[15]
Chen L, Shi H, Che Y, et al. Efficacy of endostatin combined with continuous transcatheter arterial infusion and chemoembolization on gastric cancer with liver metastasis and analysis of prognosis. J BUON 2020; 25(3): 1469-75.
[PMID: 32862592]
[16]
Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19(6): 1187-94.
[http://dx.doi.org/10.1093/emboj/19.6.1187] [PMID: 10716919]
[17]
Li H-L, Li S, Shao J-Y, et al. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene Ther 2008; 15(4): 247-56.
[http://dx.doi.org/10.1038/sj.gt.3303038] [PMID: 18097470]
[18]
Thomas A, Müller SS, Frey H, et al. Beyond poly(ethylene glycol): Linear polyglycerol as a multifunctional polyether for biomedical and pharmaceutical applications. Biomacromolecules 2014; 15(6): 1935-54.
[http://dx.doi.org/10.1021/bm5002608] [PMID: 24813747]
[19]
Li Z, Jia L, Guo L, et al. Pharmacokinetics of PEGylated recombinant human endostatin (M2ES) in rats. Acta Pharmacol Sin 2015; 36(7): 847-54.
[http://dx.doi.org/10.1038/aps.2015.16] [PMID: 26027657]
[20]
Guo L, Geng X, Chen Y, et al. Pre-clinical toxicokinetics and safety study of M2ES, a PEGylated recombinant human endostatin, in rhesus monkeys. Regul Toxicol Pharmacol 2014; 69(3): 512-23.
[http://dx.doi.org/10.1016/j.yrtph.2014.05.019] [PMID: 24878240]
[21]
Song H, Liu X, Zhang H, et al. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys1. Acta Pharmacol Sin 2005; 26(1): 124-8.
[http://dx.doi.org/10.1111/j.1745-7254.2005.00009.x] [PMID: 15659125]
[22]
Yang XX, Hu ZP, Chan E, et al. Pharmacokinetics of recombinant human endostatin in rats. Curr Drug Metab 2006; 7(6): 565-76.
[http://dx.doi.org/10.2174/138920006778017803] [PMID: 16918312]
[23]
Guo L, Li Z, Xu B, et al. Pharmacokinetics of PEGylated recombinant human endostatin in rhesus monkeys. Life Sci 2019; 238: 116967.
[http://dx.doi.org/10.1016/j.lfs.2019.116967] [PMID: 31626794]
[24]
Fu Y, Tang H, Huang Y, et al. Unraveling the mysteries of endostatin. IUBMB Life 2009; 61(6): 613-26.
[http://dx.doi.org/10.1002/iub.215] [PMID: 19472178]
[25]
Cui C, Mao L, Chi Z, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 2013; 21(7): 1456-63.
[http://dx.doi.org/10.1038/mt.2013.79] [PMID: 23670576]
[26]
Han B, Xiu Q, Wang H, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 2011; 6(6): 1104-9.
[http://dx.doi.org/10.1097/JTO.0b013e3182166b6b] [PMID: 21532504]
[27]
Li BL, Hu XL, Zhao XH, et al. Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. J Chemother 2015; 27(5): 301-6.
[http://dx.doi.org/10.1179/1973947815Y.0000000022] [PMID: 25873343]
[28]
Zhou JF, Bai CM, Wang YZ, et al. Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: A pilot study. Chin Med J 2011; 124(24): 4299-303.
[PMID: 22340403]
[29]
Rudmann DG, Alston JT, Hanson JC, et al. molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol 2013; 41(7): 970-83.
[http://dx.doi.org/10.1177/0192623312474726] [PMID: 23788571]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy